OPTIMIZATION OF THERAPY FOR ACS PATIENTS WITH PHARMACOTHERAPY

Sunday, March 9, 2025

7:00 PM – 8:45 PM ET

Moderator(s)

C. Michael Gibson, MD

Professor of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States

Disclosure(s): Amgen: Consulting Fees (e.g., advisory boards) (Ongoing); Angel Medical Systems, Inc.: Consultant (Ongoing); Bayer HealthCare: Consultant (Ongoing)
Neal S. Kleiman, MD, FACC, MSCAI

Medical Director, Cardiac Catheterization Laboratories
Houston Methodist DeBakey Heart and Vascular Center
Houston, Texas, United States

Disclosure(s): Abbott Labs: Consultant (Ongoing); Boston Scientific Corporation: Consultant (Ongoing); Edwards Lifesciences LLC: Consultant (Ongoing); Medtronic: Consultant (Ongoing)

Disclosure(s):

Marc Cohen, MD: Abbott Vascular, Edwards, Medtronic, Boston Scientific: Grant/Research Support (Ongoing); BSC, Amgen, BCRI, PERC, NAMSA, BMS, Janssen, Regeneron: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Daiichi Sankyo, Boeringer Ingelheim , Sanofi, AstraZeneca , Chiesi, Bracco, Amgen, Novo Nordisk, Philips: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

C. Michael Gibson, MD: Amgen: Consulting Fees (e.g., advisory boards) (Ongoing); Angel Medical Systems, Inc.: Consultant (Ongoing); Bayer HealthCare: Consultant (Ongoing)

Neal S. Kleiman, MD, FACC, MSCAI: Abbott Labs: Consultant (Ongoing); Boston Scientific Corporation: Consultant (Ongoing); Edwards Lifesciences LLC: Consultant (Ongoing); Medtronic: Consultant (Ongoing)